Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa

2021年12月24日 12:16:11 来自: (0)参与

Phase-IIIb trial demonstrates statistically significant outcome on the primary endpoint
Largest study to date showing benefit of Veltassa (patiromer) in high risk patient population with heart failure
Results suggest that treatment with Veltassa is beneficial in heart failure patients to control serum potassium levels
Veltassa enabled 85% of patients to be optimized to guideline-recommended doses of RAASi
Vifor Pharma to present full data at a major conference in H1 2022

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.

85% of the more than 1,000 patients with either high risk of hyperkalemia or active hyperkalemia were able to be optimized to guideline recommended, life-saving RAASi treatment, including mineralocorticoid receptor antagonists, with Veltassa® during the run-in phase of the study. This shows that the gap between guideline recommendations and real-world practice regarding the use of RAASi can be addressed with Veltassa®. Veltassa® was generally well tolerated and without unexpected safety findings. Vifor Pharma expects the key trial results to be presented at a major cardiology conference in H1 2022.

“We are delighted and very encouraged about the positive read-out from the DIAMOND trial for the heart failure patient community,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “RAASi therapy saves lives and delays disease progression, but unfortunately many patients with heart failure are insufficiently treated due to risk of hyperkalemia. Hyperkalemia is a serious condition associated with life-threatening consequences. These data support an effective management of chronic hyperkalemia in heart failure patients on optimal RAASi therapy with Veltassa®. We look forward to presenting the detailed data to the scientific community in the first half of 2022.”

“This trial makes a significant contribution to the growing body of evidence showing the importance to use Veltassa® to enable RAASi and ensures optimal treatment in a high-risk population”, commented Prof. Javed Butler, Principal Investigator for the DIAMOND study. “The totality of evidence from the trials with patiromer suggests the treatment to control serum potassium and preventing hyperkalemia in heart failure patients aiding longer term optimal medical therapy.”

Vifor Pharma continues to support several data generation programs with the ongoing phase-IV PLATINUM study and the CARE-HK in HF global registry to drive evidence-based care using Veltassa® in chronic kidney disease and heart failure patients.

About the DIAMOND trial
This global, multicenter, double-blind, placebo controlled study was designed to evaluate the potential role of Veltassa® in enabling patients with, or at high risk of, hyperkalemia to remain on RAASi therapy. On recommendation of the independent study Executive Committee and due to COVID-19 impact on recruitment, the primary endpoint has been changed in June 2021 to investigate the role of Veltassa® in controlling serum potassium, preventing hyperkalemia and maintain RAASi use in heart failure patients.

About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.

相关新闻
百度网友:迷途不知歸返
评论:姐姐曾对我说:妹子你真好看!背面看,想犯罪;侧面看,想到退;正面看,想正当防卫。

淘宝网友:宿命旳青春ノ
评论:你玩儿的叫潜水,哥玩儿的叫潜伏

网易网友:执念/173yeah°
评论:不是哥花心、只是哥对每个女孩都太过用心

其它网友:Cool| 卡其布
评论:出门顶个避雷针,从此装B再也不怕遭雷劈!

腾讯网友:Paranoid. 偏执
评论:人生四项基本原则:懂得选择,学会放弃,耐得住寂寞,经得起诱惑。

天猫网友:离心   ■
评论:有一个胖子,从二十楼顶往下跳。结果变成了… 死胖子!!

天涯网友:浅笑忧伤
评论:世界上最遥远的距离,莫过于周一到周五。

本网网友:目光瞄准 Follow
评论:> 我说:要有上班以外的生活!于是,老婆告诉我这个可以有、于是:我有了加班!

猫扑网友:m/m  撕心裂肺°
评论:我还没年轻到什么都懂的地步。

搜狐网友:笨笨Forever〃
评论:人之所以活得累是因为:放不下架子,撕不开面子,解不开情节。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin